The Omicron variant is rapidly becoming the dominant SARS-CoV-2 virus circulating globally.
It is important to define reductions in virus neutralizing activity in the serum of convalescent …

Background The ongoing coronavirus disease (COVID-19) pandemic has major impacts on
health systems, the economy and society. Assessing infection attack rates in the population …

We present an interim analysis of a registered clinical study (NCT04800133) to establish
immunobridging with various antibody and cellular immunity markers and to compare the …

Surrogate neutralization assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
that can be done without biosafety level 3 containment and in multiple species are …

Background Omicron subvariant BA.2 circulation is rapidly increasing globally. Aim We
evaluated the neutralising antibody response from vaccination or prior SARS-CoV-2 infection …

Background BA.2.12.1, BA.4 and BA.5 subvariants of SARS-CoV-2 variant-of-concern (VOC)
Omicron (B.1.1.529) are spreading globally. They demonstrate higher transmissibility and …

Background Few trials have compared homologous and heterologous third doses of COVID-19
vaccination with inactivated vaccines and mRNA vaccines. The aim of this study was to …

Introduction Two doses of inactivated SARS-CoV-2 vaccine CoronaVac cannot elicit high
efficacy against symptomatic COVID-19, especially against the Omicron variant, but that can be …

Background Limited data exist on antibody responses to mixed vaccination strategies that
involve inactivated coronavirus disease 2019 (COVID-19) vaccines, particularly in the context …

The high effectiveness of the third dose of BNT162b2 in healthy adolescents against Omicron
BA.1 has been reported in some studies, but immune responses conferring this protection …